Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is how its current share price lines up with what the business may be worth. The stock ...

Using a CRISPR-based biosensor platform, researchers have detected microRNA biomarkers of Alzheimer’s disease, with the ...

CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient ...

Gene editing is a numbers game. For any genetic tweaks to have notable impact, a sufficient number of targeted cells need to have the disease-causing gene deleted or replaced. Despite a growing ...

CRISPR Therapeutics’ fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these early quarterly numbers don’t mean much. The foreseeable future looks bright ...

A new CRISPR-based one-off procedure that lowers "bad" cholesterol is expected to enter Phase I human trial in 2026. If successful, it could be the first approved genetic-silencing method on the ...

Crispr Therapeutics remains highly volatile, disconnected from near-term fundamentals, yet I see long-term value far above current levels. CRSP's business progress is slow, with pipeline milestones ...

Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases. Last February ...